Bringing the fundamentals into focus…
Back to ARS Pharmaceuticals, Inc.
How ARS Pharmaceuticals, Inc. stacks up
SPRY · against 354 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #219 of 355 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score137 peers with a valuation score of 0–9, including SPRY · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -71.0% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -78.1% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -64.8% vs peer median 0.0%
Metric by metric
Position: dot = SPRY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SPRY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 339 reported | -71.5% | -0.4% | 5% | 30% | |
| EBITDA yieldHigher is better · 360 reported | -63.1% | 1.8% | 8% | 50% | |
| Free cash flow yieldHigher is better · 182 reported | -64.8% | -9.2% | 4% | 20% | |
| Book yieldHigher is better · 347 reported | 4.1% | 51.4% | 9% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around SPRY| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 219 | 468M USD | 8 | 40 | |
| 219 | 519M USD | 8 | 22 | |
| 219 | 223M USD | 8 | 34 | |
| 219 | 588M USD | 8 | 24 | |
| 219 | 303M USD | 8 | 27 | |
| 219 | 354M USD | 8 | 13 | |
| 219 | 467M USD | 8 | 44 | |
| 219 | 172M USD | 8 | 34 | |
| 219 | 549M USD | 8 | 30 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score